OakChart

Jyong Biotech Ltd

MENSHealthcare·Biotechnology·Taiwan·Micro·NASD·Nov 11 • 3:58 PM ET

1.74-0.05 (-2.79%)
2026-11-12 06:04 CET
Market cap
129.17 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-4.67 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.06
P/E
-
Compare

Price

MENS against its 20, 50 and 200-day averages
2050200
5.0010.0015.0020.00171K341KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MENSclose 1.7420-day 1.8450-day 2.00200-day 2.101.74

95.7% under the 52-week high of 40.83 on 11 Nov 2025. 52-week low 1.43 on 11 Feb 2026. Last 15 sessions, 38.4% high to low

Volume 0.32× normal · the line is the 50-bar volume average

Profile

MENS
52-week range, 1% of the way up
1.4340.83

Jyong Biotech Ltd. operates as a holding company, which engages in the development of biotechnology products. It offers plant-derived drugs that focus on the treatment of urinary system diseases. The company was founded by Fu Feng Kuo in July 2002 and is headquartered in New Taipei, Taiwan.

Employees27
IPOJun 17, 2025
Beta2.59
ATR, 14d0.18
Rel volume0.32
Short float0.72%
Insider own62.20%
Inst own0.73%

Snapshot

6 groups

Valuation

Index-
Market Cap129.17M
Enterprise Value146.54M
Income-4.67M
Sales0.00M
Book/sh-0.34
Cash/sh0.02
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees27
IPOJun 17, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C109.46
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.45
Current Ratio0.45
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.06
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y11.59% -2.18%
Sales past 3/5Y- -
EPS Y/Y TTM-56.02%
Sales Y/Y TTM-
EPS Q/Q-102.19%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own62.20%
Insider Trans0.00%
Inst Own0.73%
Inst Trans6.01%
ROA-34.42%
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-5.23%
SMA50-12.95%
SMA200-17.09%
Trades-

Technical

Shs Outstand74.23M
Shs Float28.06M
Short Float0.72%
Short Ratio4.74
Short Interest0.20M
52W High40.83 -95.74%
52W Low1.43 21.68%
Volatility10.09% 10.49%
ATR (14)0.18
RSI (14)42.43
Beta2.59
Rel Volume0.32
Avg Volume42.56K
Volume13,530

Performance

Perf Week0.00%
Perf Month-14.71%
Perf Quarter-15.53%
Perf Half Y-13.86%
Perf YTD-55.95%
Perf Year-95.72%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close1.79
Price1.74
Change %-2.79%

Peers

Mkt cap
TickerCompanyMkt cap
URGNUroGen Pharma Ltd1.28B
ABVCABVC BioPharma Inc26.49M
VERUVeru Inc36.49M
PRCTProcept BioRobotics Corp1.34B
TLXTelix Pharmaceuticals Ltd ADR3.31B
YDESYD Bio Ltd435.68M
LPCNLipocine Inc17.61M
MDXHMDxHealth SA13.98M
TFXTeleflex Incorporated6.20B
RGCRegencell Bioscience Holdings Ltd2.68B

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.36B
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.35B
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 107.35M

News

latest 14 of 46
  • Jyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, California (GlobeNewswire)
  • Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates (GlobeNewswire)
  • Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow (GlobeNewswire)
  • Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships (GlobeNewswire)
  • Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention (GlobeNewswire) +8.29%
  • Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview (GlobeNewswire)
  • Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 (GlobeNewswire)
  • Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio (GlobeNewswire)
  • Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2 (GlobeNewswire)
  • Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia (GlobeNewswire)
  • Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value (GlobeNewswire) -7.81%
  • Jyong Biotech Responds to Share Price and Volume Movement (GlobeNewswire)
  • Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS-2 Market Entry (GlobeNewswire)
  • Jyong Biotech Ltd. Signs Non-Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In-Licensing of Plant-Derived MCS Drugs (GlobeNewswire) +15.16%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-0.059-0.093-0.059-0.041-0.064
Period20212022202320242025
EPS, quarterly
Period
Sales, annual00000
Period20212022202320242025
Sales, quarterly
Period
Shares, annual71.56771.56774.23474.23474.234
Period20212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.100.120.130.120.12
Gross Profit0.00-0.10-0.12-0.13-0.12-0.12
Selling, General and Administrative Excl. Other2.612.511.942.672.712.28
Research and Development0.810.730.820.961.181.44
Other Operating Expense0.000.000.000.000.000.00
Operating Income-2.61-2.61-2.06-2.80-2.83-2.40
Interest Expense2.542.541.040.760.770.84
Unusual Expense0.000.000.000.000.000.00
Net Income Before Taxes-4.67-4.67-3.02-4.40-6.63-4.20
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-4.67-4.67-3.02-4.40-6.63-4.20
Net Income From Continuing Operations-4.67-4.67-3.02-4.40-6.63-4.20
Net Income-4.67-4.67-3.02-4.40-6.63-4.20
EPS (Recurring)-0.06-0.06-0.04-0.06-0.09-0.06
EPS (Basic, Before Extraordinaries)-0.06-0.06-0.04-0.06-0.09-0.06
EPS (Diluted)-0.06-0.06-0.04-0.06-0.09-0.06
EBITDA--2.51-1.94-2.67-2.71-2.28
Non-Operating Income (Expense)0.480.480.07-0.85-3.04-0.96
Other After Tax Adjustments0.000.000.000.000.000.00
Shares Outstanding74.2374.2374.2374.2371.5771.57
Market Capitalization129.17129.17313.27---

Income statement, quarterly

Currency USD, millions
Metric2025S22025S12024S22024S1
Total Revenue0.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.060.06
Gross Profit0.000.00-0.06-0.06
Selling, General and Administrative Excl. Other1.790.821.050.89
Research and Development0.450.370.380.45
Other Operating Expense0.000.000.000.00
Operating Income-1.79-0.82-1.10-0.95
Interest Expense2.120.420.590.45
Unusual Expense0.000.000.000.00
Net Income Before Taxes-3.42-1.25-1.69-1.33
Income Taxes0.000.000.000.00
Consolidated Net Income-3.42-1.25-1.69-1.33
Net Income From Continuing Operations-3.42-1.25-1.69-1.33
Net Income-3.42-1.25-1.69-1.33
EPS (Recurring)-0.05-0.02-0.02-0.02
EPS (Basic, Before Extraordinaries)-0.05-0.02-0.02-0.02
EPS (Diluted)-0.05-0.02-0.02-0.02
EBITDA---1.05-0.89
Non-Operating Income (Expense)0.49-0.02-0.000.07
Shares Outstanding74.2374.2374.2374.23
Market Capitalization129.17630.99705.22-

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments1.180.101.742.372.38
Short Term Receivables13.510.000.000.000.00
Inventories0.000.000.000.000.00
Other Current Assets0.850.100.100.100.26
Total Current Assets15.540.211.842.462.65
Net Property, Plant & Equipment5.235.225.686.006.78
Total Investments and Advances0.000.000.000.000.00
Other Assets0.010.940.730.280.01
Total Assets20.786.378.258.749.43
Short Term Debt Incl. Current Port. of LT Debt8.367.448.107.825.18
Accounts Payable0.000.000.000.000.05
Other Current Liabilities26.454.686.155.081.06
Total Current Liabilities34.8112.1314.2612.916.29
Long Term Debt10.1910.698.596.436.61
Provision for Risks Charges0.0019.3818.7918.4118.00
Other Liabilities0.690.690.690.631.86
Total Liabilities45.6842.8842.3238.3832.76
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity-24.91-36.52-34.07-29.63-23.32
Total Shareholders Equity-24.91-36.52-34.07-29.63-23.32
Accumulated Minority Interest0.000.000.000.000.00
Total Equity-24.91-36.52-34.07-29.63-23.32
Total Liabilities & Stockholders Equity20.786.378.258.749.43
Book Value Per Share-0.34-0.49-0.46-0.41-0.33
Tangible Book Value Per Share-0.34-0.49-0.46-0.41-0.33
Full-Time Employees272931--
Price to Book Ratio-5.19-8.58---
Return on Assets-34.42-41.32-51.79-72.95-
Quick Ratio0.450.020.130.190.42
Current Ratio0.450.020.130.190.42

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income--4.67-3.02-4.40-6.63-4.20
Depreciation-0.100.120.130.120.12
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00
Other Funds (Non Cash)--19.210.760.550.600.85
Funds from Operations--23.78-2.14-3.72-5.91-3.23
Extraordinary Item-0.000.000.000.000.00
Changes in Working Capital-20.74-1.491.253.101.33
Cash from Operating Activities--3.04-3.62-2.47-2.81-1.90
Capital Expenditures-0.000.000.00-0.25-0.14
Net Assets From Acquisitions-0.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.000.000.00
Purchase or Sale of Investments-0.000.000.00-0.29-1.83
Purchase of Investments--16.870.000.00-0.29-1.83
Sale Or Maturity of Investments-16.870.000.000.000.00
Other Uses--15.000.000.000.000.00
Other Sources-1.490.000.101.930.66
Cash from Investing Activities--13.510.000.101.39-1.31
Cash Dividends Paid-0.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Change in Capital Stock-17.770.000.000.000.00
Repurchase of Common Pref Stock-0.000.000.000.000.00
Sale of Common Pref Stock-17.770.000.000.000.00
Proceedsfrom Stock Options-17.770.000.000.000.00
Issuance or Reduction of Debt, Net--0.022.202.473.61-1.35
Change in Long Term Debt--0.06-0.07-0.12-0.29-0.15
Issuance of Long Term Debt-0.000.000.000.000.02
Reduction of Long Term Debt--0.06-0.07-0.12-0.29-0.17
Net Financing Active Other Cash Flow--0.11-0.21-0.45-0.28-0.04
Other Financing Activities Uses--0.11-0.21-0.45-0.28-0.04
Cash from Financing Activities-17.631.992.033.33-1.38
Exchange Rate Effect--0.01-0.01-0.05-0.030.07
Net Change in Cash-1.08-1.64-0.401.89-4.52
Free Cash Flow--3.04-3.62-2.47-3.06-2.03

Balance sheet, quarterly

Currency USD, millions
Metric2025S22025S12024S22024S1
Cash & Short Term Investments1.1817.010.100.10
Short Term Receivables13.510.000.000.00
Inventories0.000.000.000.00
Other Current Assets0.850.150.100.10
Total Current Assets15.5417.160.210.20
Net Property, Plant & Equipment5.235.505.225.40
Total Investments and Advances0.000.000.000.00
Other Assets0.010.010.940.84
Total Assets20.7837.676.376.44
Short Term Debt Incl. Current Port. of LT Debt8.3622.927.447.62
Accounts Payable0.000.000.000.01
Other Current Liabilities26.454.634.684.30
Total Current Liabilities34.8127.5512.1311.93
Long Term Debt10.1912.2810.699.75
Other Liabilities0.690.690.690.69
Total Liabilities45.6860.1442.8841.37
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00
Common Equity-24.91-22.47-36.52-34.93
Total Shareholders Equity-24.91-22.47-36.52-34.93
Accumulated Minority Interest0.000.000.000.00
Total Equity-24.91-22.47-36.52-34.93
Total Liabilities & Stockholders Equity20.7837.676.376.44
Book Value Per Share-0.34-0.30-0.49-0.47
Tangible Book Value Per Share-0.34-0.30-0.49-0.47
Price to Book Ratio-5.19-17.28-19.31-
Return on Assets-34.42-13.35--
Quick Ratio0.450.620.020.02
Current Ratio0.450.620.020.02

Cash flow, quarterly

Currency USD, millions
Metric2025S22025S12024S22024S1
Net Income---1.69-1.33
Depreciation--0.060.06
Other Funds (Non Cash)--0.460.30
Funds from Operations---1.17-0.97
Extraordinary Item--0.000.00
Changes in Working Capital--0.26-1.74
Cash from Operating Activities---0.91-2.71
Capital Expenditures--0.000.00
Net Assets From Acquisitions--0.000.00
Sale of Fixed Assets and Businesses--0.000.00
Purchase or Sale of Investments--0.000.00
Purchase of Investments--0.000.00
Sale Or Maturity of Investments--0.000.00
Other Uses--0.000.00
Other Sources--0.000.00
Cash from Investing Activities--0.000.00
Cash Dividends Paid--0.000.00
Preferred Dividends (Cash Flow)--0.000.00
Change in Capital Stock--0.000.00
Repurchase of Common Pref Stock--0.000.00
Sale of Common Pref Stock--0.000.00
Proceedsfrom Stock Options--0.000.00
Issuance or Reduction of Debt, Net--0.951.25
Change in Long Term Debt---0.03-0.04
Issuance of Long Term Debt--0.000.00
Reduction of Long Term Debt---0.03-0.04
Net Financing Active Other Cash Flow---0.10-0.11
Other Financing Activities Uses---0.10-0.11
Cash from Financing Activities--0.851.14
Exchange Rate Effect--0.01-0.01
Net Change in Cash---0.06-1.58
Free Cash Flow---0.91-2.71

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.72%0.2M28.1M42.49K
2026-10-150.76%0.2M28.1M45.69K
2026-09-300.79%0.2M28.1M50.84K
2026-09-150.87%0.2M28.1M72.14K
2026-08-310.68%0.2M28.1M86.31K
2026-08-140.63%0.2M28.1M89.67K
2026-07-310.64%0.2M28.1M92.68K
2026-07-150.86%0.2M28.1M96.96K
2026-06-300.74%0.2M28.1M109.08K
2026-06-151.17%0.3M28.1M112.61K
2026-05-290.89%0.2M28.1M125.54K
2026-05-150.86%0.2M28.1M189.65K
2026-04-300.69%0.2M28.1M245.39K
2026-04-150.47%0.1M28.1M306.08K
2026-03-310.83%0.2M28.1M345.50K
2026-03-131.03%0.3M28.1M952.43K
2026-02-271.33%0.4M28.1M917.00K
2026-02-131.65%0.5M28.1M887.41K
2026-01-301.69%0.5M28.1M896.54K
2026-01-151.87%0.5M28.1M881.36K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.004.900.700.0001.000.000.0000.0000.000
call5.000.004.900.000.0000.000.000.0000.0000.000
call7.500.004.900.000.0000.000.000.0000.0000.000
put2.500.004.901.540.0005.000.000.0000.0000.000
put5.000.805.500.000.0000.000.000.0000.0000.000
put7.503.308.005.200.0001.000.000.0000.0000.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-05-1520-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-04-29NT 20-F2025-12-31SEC
2026-04-24SCHEDULE 13DSEC
2026-04-143Initial statement of beneficial ownership of securities2026-04-13SEC
2026-04-083Initial statement of beneficial ownership of securities2026-04-08SEC
2026-04-013Initial statement of beneficial ownership of securities2026-04-01SEC
2026-04-013Initial statement of beneficial ownership of securities2026-04-01SEC
2026-04-013Initial statement of beneficial ownership of securities2026-04-01SEC
2026-04-013Initial statement of beneficial ownership of securities2026-04-01SEC
2026-04-013Initial statement of beneficial ownership of securities2026-04-01SEC
2026-02-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-06SEC
2026-01-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-09SEC
2025-06-30SP 15D2Special Financial Report filed under Rule 15d-22024-12-31SEC
2025-06-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-06-18SEC
2025-06-18424B4SEC
2025-06-16EFFECTEffectiveness filing by commission orderSEC
2025-06-16CERTSEC
2025-06-128-A12BSEC
2025-06-12CORRESPSEC
2025-06-12CORRESPSEC
2025-06-06POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2025-04-23POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2025-03-31EFFECTEffectiveness filing by commission orderSEC
2025-03-28CORRESPSEC
2025-03-28CORRESPSEC
2025-03-27FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2025-03-27FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2025-03-11F-1/ASEC
2025-02-18FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2025-02-07FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.0.35%
GEODE CAPITAL MANAGEMENT, LLC0.10%
HRT FINANCIAL LP0.07%
XTX Topco Ltd0.04%
RENAISSANCE TECHNOLOGIES LLC0.03%
CITIGROUP INC0.03%
StoneX Group Inc.0.02%
China Universal Asset Management Co., Ltd.0.02%
State of Wyoming0.02%
BARCLAYS PLC0.01%

Funds

Fund% owned
iShares Biotechnology ETF0.28%
Fidelity Nasdaq Composite Index Fund0.06%
Fidelity Nasdaq Composite Index ETF0.04%
Invesco Nasdaq Biotechnology ETF0.01%
ProShares Ultra Nasdaq Biotechnology0.00%

OakChart. MENS. Cached 15 minutes.

Some panels did not load: ratings, insider.